Introduction
Methotrexate was first developed for treatment of leukemia in 1940 1 . Now, it is used widely. It plays important role to halt pathology of various diseases such as rheumatoid arthritis 2 . In Rheumatoid arthritis it acts both by its anti-inflammatory and immunosuppressive effects 3 . Rheumatoid arthritis is not a fully curable disease. However, different types of treatment can be used to alleviate symptoms. Drugs therapy can be divided into DMARDs, analgesics and antiinflammatory drugs, glucocorticoids, TNF-a blockers and interleukin-1 blocker. As DMARDs methotrexate is most widely used drug and has been found to produce durable remissions and delay or halt disease progression 4 . But methotrexate may affects adversely on various system 5 specially on liver 6 
Results
Out of 30 patients 12 were male and 18 were female with a male: female-2:3. Mean age of the study population was 36.70±8.95 years. Occupational distribution reveals most of the patients (40%) were housewife followed by farmer (30%), service holder (20%) and businessmen (10%) (Fig.-1) .
Fig.1: Occupational distribution of patients (n=30)
After getting methotrexate therapy for 6 weeks most of the patients (60%) showed marked improvement of symptoms (Table-1) .
Table-I: Percentages of Clinical improvement of the patients (n=30)
Prothrombin time was analyzed and it revealed changes of prothrombin time was not significant after 6 weeks of methotrexate therapy (Table-II 
Discussion
Marked (>40% joint symptoms improvements) improvement of joint symptoms occurred in 60% patients. Some researchers observed the beneficial effects of methotrexate. Weinblatt ME et al 8 , (1998) showed marked improvemet occurred more than 50% patients. Improvement of 69% patients occurred in another study 9 . Our study is in well agreement with those studies.
In this study female are affected more than male. Several studies showed female were more affected than male 10, 11 which is also in agreement with our study. The peak incidence of rheumatoid arthritis is in third and fifth decades of life 10 . In the present study mean age of the patients was 36.7 years which was in well agreement with above study. In present study, only occupational distribution of patients was revealed but difference of methotrexate effects was not studied. In present study no significant changes observed in prothrombin time during methotrexate therapy. We did not exclude exposure to coumarin drugs and vitamin k deficiency that may increase prothrombin time 12 . From observations from this study we can assume that methotrexate does not alter the synthetic function of liver.
Conclusion
From the results it can be concluded that methotrexate therapy in rheumatoid arthritis could not alter Prothrombin time. Hence methotrexate can be useful as DMARDs in treatment of rheumatoid arthritis with close monitoring. Further study on large population may clarify therapeutic exploration.
